With a greater number of individuals being affected by neurological diseases such as Parkinson’s disease, tremors, chronic pain, migraine and depressive episodes, Japan is striving to find innovative solutions. In this context, the neuromodulation devices market in Japan is expected to grow at a compound annual growth rate (CAGR) of around 6% through 2033, according to GlobalData, a prominent data and analytics company.

Amidst the groundbreaking innovations, Japan spearheads the Asia-Pacific (APAC) neuromodulation devices market, demonstrating a steadfast commitment to advancing neurological health solutions.

GlobalData’s report, “Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that Japan emerged as the predominant market share holder within the APAC region, constituting approximately 35% of the market in 2023.

Soumya Shraddhya Paul, Medical Devices Analyst at GlobalData, comments: “The increasing demand for neuromodulation devices such as deep brain, spinal cord, vagus nerve, and peripheral nerve stimulators underscores their efficacy in mitigating pain, particularly in individuals with neurological disorders. These treatments offer targeted relief, significantly improving individuals’ quality of life.”

In January 2024, Neurolief, in partnership with Sawai Pharmaceutical Co Ltd, has gained approval from the Japanese Ministry of Health, Labor, and Welfare for Relivion, an at-home neuromodulation device for acute migraines. This milestone positions Relivion as the first of its kind in Japan.

Utilizing advanced non-invasive brain neuromodulation technology, it simultaneously stimulates occipital and trigeminal nerve branches, providing an effective solution for migraines. The system integrates a patient mobile app and a cloud-enabled physician interface for the seamless artificial intelligence incorporation and remote monitoring. This regulatory approval indicates a significant advancement, enhancing accessibility to innovative migraine treatment in Japan.

Paul concludes: “With an emphasis on treating migraines and chronic pain through non-invasive technology and remote monitoring, the availability of devices such Neurolief signifies a transformative shift in the Japanese market for neuromodulation devices, which is growing due to technological advancements and the integration of artificial intelligence.”